Date: 2014-05-08
Type of information: Series B financing round
Company: Imaginab (USA - CA)
Investors: Mérieux Développement (France) Novartis Venture Funds (Switzerland) Cycad Group (USA) Nextech Invest
Amount: $21 Million
Funding type: series B financing round
Planned used: ImaginAb is redefining therapeutic management by harnessing the power of antibody technology for in vivo imaging. The company’s proprietary antibody fragment platform yields actionable molecular information to guide treatment decisions in cancer and immunology. ImaginAb also collaborates with select biopharmaceutical partners to design imaging agents as companion diagnostics for therapeutic antibodies. Imaginab will use these funds to accelerate the development of its lead program in prostate cancer IAB2M and continue to expand its product pipeline. IAB2M is a PSMA (Prostate-specific membrane antigen) minibody currently in phase 1/2a. ImaginAb’s pipeline includes CD3 and CD8 “immunoPET” imaging programs to deliver a clearer understanding of the role of immune function and response in a variety of disease settings, including cancer and autoimmune diseases.
Others: * On May. 8, 2014, ImaginAb, a clinical stage biotechnology company that engineers antibodies into smaller protein formats optimized for in vivo molecular imaging, announced the completion of a $21M Series B financing of the company, led by Mérieux Développement and syndicated with Novartis Venture Funds, Cycad Group and Nextech Invest.
Therapeutic area: Cancer - Oncology - Autoimmune diseases
